Mechanisms of neurodegeneration in Huntington’s disease

Huntington’s disease (HD) is caused by an expansion of cytosine–adenine–guanine (CAG) repeats in the huntingtin gene, which leads to neuronal loss in the striatum and cortex and to the appearance of neuronal intranuclear inclusions of mutant huntingtin. Huntingtin plays a role in protein trafficking, vesicle transport, postsynaptic signaling, transcriptional regulation, and apoptosis. Thus, a loss of function of the normal protein and a toxic gain of function of the mutant huntingtin contribute to the disruption of multiple intracellular pathways. Furthermore, excitotoxicity, dopamine toxicity, metabolic impairment, mitochondrial dysfunction, oxidative stress, apoptosis, and autophagy have been implicated in the progressive degeneration observed in HD. Nevertheless, despite the efforts of a multidisciplinary scientific community, there is no cure for this devastating neurodegenerative disorder. This review presents an overview of the mechanisms that may contribute for HD pathogenesis. Ultimately, a better understanding of these mechanisms will lead to the development of more effective therapeutic targets.

[1]  Jennifer Goldman,et al.  Huntington disease , 2010, Principles and Practice of Movement Disorders.

[2]  S. Kuo,et al.  Depletion of mitochondrial DNA in leukocytes of patients with poly-Q diseases , 2008, Journal of the Neurological Sciences.

[3]  F. Melchior,et al.  Concepts in sumoylation: a decade on , 2007, Nature Reviews Molecular Cell Biology.

[4]  L. Raymond,et al.  Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load , 2007, The Journal of physiology.

[5]  S. Hersch,et al.  Neuroprotective Effects of Synaptic Modulation in Huntington's Disease R6/2 Mice , 2007, The Journal of Neuroscience.

[6]  R. Atwal,et al.  Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. , 2007, Human molecular genetics.

[7]  J. Olson,et al.  Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration , 2007, The Journal of Neuroscience.

[8]  J. Cooper,et al.  Clinical correlates of mitochondrial function in Huntington's disease muscle , 2007, Movement disorders : official journal of the Movement Disorder Society.

[9]  S. Schreiber,et al.  Small Molecule Enhancers of Rapamycin-Induced TOR Inhibition Promote Autophagy, Reduce Toxicity in Huntington’s Disease Models and Enhance Killing of Mycobacteria by Macrophages , 2007, Autophagy.

[10]  Howard Schulman,et al.  Global changes to the ubiquitin system in Huntington's disease , 2007, Nature.

[11]  Yih-Ru Wu,et al.  Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. , 2007, Biochemical and biophysical research communications.

[12]  Xi Chen,et al.  Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease , 2007, The Journal of Neuroscience.

[13]  Alexandra Durr,et al.  Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression , 2007, PloS one.

[14]  T. Videen,et al.  Normal platelet mitochondrial complex I activity in Huntington’s Disease , 2007, Neurobiology of Disease.

[15]  M. Hayden,et al.  Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s disease , 2007, Neuroscience.

[16]  S. Schreiber,et al.  Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. , 2007, Nature chemical biology.

[17]  J. Olson,et al.  Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration , 2007, PLoS genetics.

[18]  J. Roder,et al.  NMDA Receptor Function and NMDA Receptor-Dependent Phosphorylation of Huntingtin Is Altered by the Endocytic Protein HIP1 , 2007, The Journal of Neuroscience.

[19]  D. Rubinsztein,et al.  Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and α-Synuclein* , 2007, Journal of Biological Chemistry.

[20]  M. MacDonald,et al.  Huntingtin inhibits caspase‐3 activation , 2006, The EMBO journal.

[21]  A. Parent,et al.  The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. , 2006, Brain : a journal of neurology.

[22]  M. Russo,et al.  Increased apoptosis, huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects , 2006, Cell Death and Differentiation.

[23]  Shihua Li,et al.  Context-dependent Dysregulation of Transcription by Mutant Huntingtin* , 2006, Journal of Biological Chemistry.

[24]  S. Luquet,et al.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. , 2006, Cell metabolism.

[25]  M. Hayden,et al.  Mitochondrial-Dependent Ca2+ Handling in Huntington's Disease Striatal Cells: Effect of Histone Deacetylase Inhibitors , 2006, The Journal of Neuroscience.

[26]  Jiandie D. Lin,et al.  Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.

[27]  Dimitri Krainc,et al.  Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.

[28]  C. Ross,et al.  Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin , 2006, Neurobiology of Disease.

[29]  F. Jiménez-Jiménez,et al.  Oxidative Stress in Skin Fibroblasts Cultures of Patients with Huntington’s Disease , 2006, Neurochemical Research.

[30]  Michael P. Cusack,et al.  Huntingtin Phosphorylation Sites Mapped by Mass Spectrometry , 2006, Journal of Biological Chemistry.

[31]  M. MacDonald,et al.  Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice , 2006, Neurobiology of Disease.

[32]  L. Raymond,et al.  Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin , 2006, Cell.

[33]  Wei Li,et al.  Expression and Characterization of Full-length Human Huntingtin, an Elongated HEAT Repeat Protein* , 2006, Journal of Biological Chemistry.

[34]  S. Augood,et al.  Huntingtin inclusions do not down‐regulate specific genes in the R6/2 Huntington's disease mouse , 2006, The European journal of neuroscience.

[35]  Alexei Degterev,et al.  Regulation of Intracellular Accumulation of Mutant Huntingtin by Beclin 1* , 2006, Journal of Biological Chemistry.

[36]  S. Tabrizi,et al.  Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. , 2006, Human molecular genetics.

[37]  Lu Gan,et al.  Palmitoylation of huntingtin by HIP14is essential for its trafficking and function , 2006, Nature Neuroscience.

[38]  M. MacDonald,et al.  Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease , 2006, Neurobiology of Disease.

[39]  M. DiFiglia,et al.  Lysosomal proteases are involved in generation of N-terminal huntingtin fragments , 2006, Neurobiology of Disease.

[40]  C. Oliveira,et al.  Caspase‐dependent and ‐independent cell death induced by 3‐nitropropionic acid in rat cortical neurons , 2006, Journal of cellular biochemistry.

[41]  M. Levine,et al.  Changes in Expression of N-Methyl-D-Aspartate Receptor Subunits Occur Early in the R6/2 Mouse Model of Huntington’s Disease , 2006, Developmental Neuroscience.

[42]  O. Riess,et al.  Normal sensitivity to excitotoxicity in a transgenic Huntington's disease rat , 2006, Brain Research Bulletin.

[43]  J. Olson,et al.  Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.

[44]  J. Rothman,et al.  Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway , 2006, The Journal of cell biology.

[45]  Xiao-Jiang Li,et al.  Interaction of Huntingtin-associated Protein-1 with Kinesin Light Chain , 2006, Journal of Biological Chemistry.

[46]  L. Thompson,et al.  Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation , 2006, Mechanisms of Ageing and Development.

[47]  D. Rubinsztein,et al.  Rapamycin alleviates toxicity of different aggregate-prone proteins. , 2006, Human molecular genetics.

[48]  Andrea Ciarmiello,et al.  Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  M. Hayden,et al.  Wild‐type huntingtin protects neurons from excitotoxicity , 2006, Journal of neurochemistry.

[50]  Ji-Yeon Shin,et al.  Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.

[51]  R. Kopito,et al.  HDAC6 and Microtubules Are Required for Autophagic Degradation of Aggregated Huntingtin* , 2005, Journal of Biological Chemistry.

[52]  D. Blum,et al.  3‐Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease , 2005, Journal of neurochemistry.

[53]  C. Cepeda,et al.  Alterations in N‐methyl‐D‐aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease , 2005, Journal of neuroscience research.

[54]  M. MacDonald,et al.  HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. , 2005, Human molecular genetics.

[55]  J. Pruim,et al.  Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease , 2005, Neurology.

[56]  Atsushi Iwata,et al.  Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[57]  B Fischl,et al.  Regional cortical thinning in preclinical Huntington disease and its relationship to cognition , 2005, Neurology.

[58]  G. Johnson,et al.  Mitochondrial Respiration and ATP Production Are Significantly Impaired in Striatal Cells Expressing Mutant Huntingtin* , 2005, Journal of Biological Chemistry.

[59]  Josephine C. Dorsman,et al.  Mutant huntingtin represses CBP, but not p300, by binding and protein degradation , 2005, Molecular and Cellular Neuroscience.

[60]  C. Pagès,et al.  Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. Hayden,et al.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Snyder,et al.  p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease , 2005, Neuron.

[63]  P. Brundin,et al.  Synaptic dysfunction in Huntington’s disease: a new perspective , 2005, Cellular and Molecular Life Sciences CMLS.

[64]  B. Landwehrmeyer,et al.  Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[65]  Lu Gan,et al.  Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. , 2005, Human molecular genetics.

[66]  D. Rubinsztein,et al.  Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases , 2005, The Journal of cell biology.

[67]  Paolo Guidetti,et al.  A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease , 2005, Nature Genetics.

[68]  S. Nemoto,et al.  SIRT1 Functionally Interacts with the Metabolic Regulator and Transcriptional Coactivator PGC-1α* , 2005, Journal of Biological Chemistry.

[69]  M. Panas,et al.  Plasma testosterone in male patients with Huntington's disease: Relations to severity of illness and dementia , 2005, Annals of neurology.

[70]  Christian Néri,et al.  Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons , 2005, Nature Genetics.

[71]  M. Levine,et al.  Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice. , 2005, Journal of neurophysiology.

[72]  J. Epplen,et al.  NR2A and NR2B receptor gene variations modify age at onset in Huntington disease , 2005, Neurogenetics.

[73]  Carlos Cepeda,et al.  Increased GABAergic function in mouse models of Huntington's disease: Reversal by BDNF , 2004, Journal of neuroscience research.

[74]  S. Augood,et al.  Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease , 2004, Neurobiology of Disease.

[75]  C. Oliveira,et al.  FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures , 2004, Neurobiology of Disease.

[76]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[77]  G. Bates,et al.  Huntingtin and the molecular pathogenesis of Huntington's disease , 2004, EMBO reports.

[78]  M. MacDonald,et al.  Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. , 2004, Human molecular genetics.

[79]  Fabrice P Cordelières,et al.  Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.

[80]  Peter Breuer,et al.  Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. , 2004, Molecular cell.

[81]  I. Kohane,et al.  Gene regulation and DNA damage in the ageing human brain , 2004, Nature.

[82]  E. Nagata,et al.  Autophagosome-like vacuole formation in Huntington's disease lymphoblasts , 2004, Neuroreport.

[83]  J. Penney,et al.  Differential loss of striatal projection systems in Huntington’s disease: a quantitative immunohistochemical study , 2004, Journal of Chemical Neuroanatomy.

[84]  Francesco Scaravilli,et al.  Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease , 2004, Nature Genetics.

[85]  P. Pandolfi,et al.  SUMO Modification of Huntingtin and Huntington's Disease Pathology , 2004, Science.

[86]  J. Pedraza-Chaverri,et al.  Increased Formation of Reactive Oxygen Species, but No Changes in Glutathione Peroxidase Activity, in Striata of Mice Transgenic for the Huntington's Disease Mutation , 2004, Neurochemical Research.

[87]  Karen Marder,et al.  Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Xiao-Jiang Li,et al.  Huntingtin-protein interactions and the pathogenesis of Huntington's disease. , 2004, Trends in genetics : TIG.

[89]  Wilhelm Gaus,et al.  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.

[90]  M. MacDonald,et al.  The serum‐ and glucocorticoid‐induced kinase SGK inhibits mutant huntingtin‐induced toxicity by phosphorylating serine 421 of huntingtin , 2004, The European journal of neuroscience.

[91]  L. Thompson,et al.  Autophagy regulates the processing of amino terminal huntingtin fragments. , 2003, Human molecular genetics.

[92]  David W. Miller,et al.  Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. , 2003, Brain research. Molecular brain research.

[93]  Aaron Ciechanover,et al.  The Ubiquitin Proteasome System in Neurodegenerative Diseases Sometimes the Chicken, Sometimes the Egg , 2003, Neuron.

[94]  C. Oliveira,et al.  Mitochondrial Dysfunction and Reactive Oxygen Species in Excitotoxicity and Apoptosis: Implications for the Pathogenesis of Neurodegenerative Diseases , 2003, Neurochemical Research.

[95]  Patrik Brundin,et al.  Huntington's disease: a synaptopathy? , 2003, Trends in molecular medicine.

[96]  Susanna M. Grzeschik,et al.  Neurodegeneration in Striatum Induced by the Mitochondrial Toxin 3-Nitropropionic Acid: Role of Matrix Metalloproteinase-9 in Early Blood-Brain Barrier Disruption? , 2003, The Journal of Neuroscience.

[97]  Andrea Crotti,et al.  Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes , 2003, Nature Genetics.

[98]  C. Parsons,et al.  Expression of Polyglutamine-expanded Huntingtin Induces Tyrosine Phosphorylation of N-Methyl-D-aspartate Receptors* , 2003, Journal of Biological Chemistry.

[99]  E. Marcora,et al.  Stimulation of NeuroD activity by huntingtin and huntingtin-associated proteins HAP1 and MLK2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[100]  M. Hayden,et al.  Huntingtin and Huntingtin-Associated Protein 1 Influence Neuronal Calcium Signaling Mediated by Inositol-(1,4,5) Triphosphate Receptor Type 1 , 2003, Neuron.

[101]  M. Chesselet,et al.  The use of transgenic and knock-in mice to study Huntington’s disease , 2003, Cytogenetic and Genome Research.

[102]  H. Paulson,et al.  Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration. , 2003, Current opinion in genetics & development.

[103]  N Makris,et al.  Evidence for more widespread cerebral pathology in early HD , 2003, Neurology.

[104]  D. Rubinsztein,et al.  Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.

[105]  M. Rechsteiner,et al.  Are Huntington's and polyglutamine-based ataxias proteasome storage diseases? , 2003, The international journal of biochemistry & cell biology.

[106]  M. Chesselet,et al.  Apoptosis in Huntington's disease , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[107]  Carlos Cepeda,et al.  Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.

[108]  A. Young Huntingtin in health and disease. , 2003, The Journal of clinical investigation.

[109]  K. Marder,et al.  Weight loss in early stage of Huntington’s disease , 2002, Neurology.

[110]  D. Tagle,et al.  PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. , 2002, Human molecular genetics.

[111]  C. Ross,et al.  Polyglutamine Repeat Length-Dependent Proteolysis of Huntingtin , 2002, Neurobiology of Disease.

[112]  B. Escalante,et al.  Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington’s disease mutation , 2002, Brain Research.

[113]  F. Squitieri,et al.  CAG mutation effect on rate of progression in Huntington's disease , 2002, Neurological Sciences.

[114]  James R. Burke,et al.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.

[115]  L. Ellerby,et al.  Calpain Activation in Huntington's Disease , 2002, The Journal of Neuroscience.

[116]  A. Deckel,et al.  Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington’s disease transgenic mice , 2002, Brain Research.

[117]  Fabrice P Cordelières,et al.  The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.

[118]  Dimitri Krainc,et al.  Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.

[119]  P. Brundin,et al.  Maintenance of Susceptibility to Neurodegeneration Following Intrastriatal Injections of Quinolinic Acid in a New Transgenic Mouse Model of Huntington's Disease , 2002, Experimental Neurology.

[120]  Rainer Duden,et al.  Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. , 2002, Human molecular genetics.

[121]  L. Raymond,et al.  Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.

[122]  A. Dale,et al.  Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.

[123]  Pascal Kahlem,et al.  Perinuclear localization of huntingtin as a consequence of its binding to microtubules through an interaction with beta-tubulin: relevance to Huntington's disease. , 2002, Journal of cell science.

[124]  J. Nevins,et al.  Huntingtin Is Present in the Nucleus, Interacts with the Transcriptional Corepressor C-terminal Binding Protein, and Represses Transcription* , 2002, The Journal of Biological Chemistry.

[125]  He Li,et al.  Interaction of Huntington Disease Protein with Transcriptional Activator Sp1 , 2002, Molecular and Cellular Biology.

[126]  M. Tsai,et al.  Neogenesis of β-cells in adult BETA2/NeuroD-deficient mice , 2002 .

[127]  A. Hackam,et al.  Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi , 2002, Nature Cell Biology.

[128]  G. Rebec,et al.  Dysregulation of Ascorbate Release in the Striatum of Behaving Mice Expressing the Huntington's Disease Gene , 2002, The Journal of Neuroscience.

[129]  C. Cepeda,et al.  Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.

[130]  A. Deckel,et al.  Reduced activity and protein expression of NOS in R6/2 HD transgenic mice: effects of l-NAME on symptom progression , 2001, Brain Research.

[131]  C. Cepeda,et al.  NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.

[132]  R. Hen,et al.  Proteasomal-Dependent Aggregate Reversal and Absence of Cell Death in a Conditional Mouse Model of Huntington's Disease , 2001, The Journal of Neuroscience.

[133]  G. Bernardi,et al.  Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene , 2001, The European journal of neuroscience.

[134]  Z. Qin,et al.  Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[135]  A. Mahal,et al.  Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice , 2001, Neurobiology of Disease.

[136]  A. Morton,et al.  Abnormalities in the synaptic vesicle fusion machinery in Huntington’s disease , 2001, Brain Research Bulletin.

[137]  R. Albin,et al.  Vesicular neurotransmitter transporters in Huntington's disease: Initial observations and comparison with traditional synaptic markers , 2001, Synapse.

[138]  O. Hansson,et al.  Partial resistance to malonate‐induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length , 2001, Journal of neurochemistry.

[139]  P. Reddy,et al.  Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95* , 2001, The Journal of Biological Chemistry.

[140]  L. Bäckman,et al.  Dopamine and cognitive functioning: brain imaging findings in Huntington's disease and normal aging. , 2001, Scandinavian journal of psychology.

[141]  A. Sawa Mechanisms for neuronal cell death and dysfunction in Huntington's disease: pathological cross-talk between the nucleus and the mitochondria? , 2001, Journal of Molecular Medicine.

[142]  D. Rigamonti,et al.  Huntingtin's Neuroprotective Activity Occurs via Inhibition of Procaspase-9 Processing* , 2001, The Journal of Biological Chemistry.

[143]  E A Zemskov,et al.  Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. , 2001, Human molecular genetics.

[144]  D. Joel,et al.  Open interconnected model of basal ganglia‐thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[145]  H. Lehrach,et al.  Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. , 2001, Molecular biology of the cell.

[146]  J. Pedraza-Chaverri,et al.  Comparative Analysis of Superoxide Dismutase Activity between Acute Pharmacological Models and a Transgenic Mouse Model of Huntington's Disease , 2001, Neurochemical Research.

[147]  K. Sieradzan,et al.  The selective vulnerability of nerve cells in Huntington's disease , 2001, Neuropathology and applied neurobiology.

[148]  T. Foroud,et al.  Progression of symptoms in the early and middle stages of Huntington disease. , 2001, Archives of neurology.

[149]  J. Hodgson,et al.  Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. , 2001, American journal of human genetics.

[150]  Michael R. Hayden,et al.  Mutant Huntingtin Enhances Excitotoxic Cell Death , 2001, Molecular and Cellular Neuroscience.

[151]  A. Morton,et al.  Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease , 2001, Journal of neurochemistry.

[152]  D. Rubinsztein,et al.  The molecular biology of Huntington's disease , 2001, Psychological Medicine.

[153]  A. Tobin,et al.  Huntington's disease: the challenge for cell biologists. , 2000, Trends in cell biology.

[154]  Michael S. Levine,et al.  Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice , 2000, Nature Genetics.

[155]  A. Morton,et al.  Mice Transgenic for the Huntington's Disease Mutation Are Resistant to Chronic 3‐Nitropropionic Acid‐Induced Striatal Toxicity , 2000, Journal of neurochemistry.

[156]  M. DiFiglia,et al.  Huntingtin Expression Stimulates Endosomal–Lysosomal Activity, Endosome Tubulation, and Autophagy , 2000, The Journal of Neuroscience.

[157]  A. F. Neuwald,et al.  HEAT repeats associated with condensins, cohesins, and other complexes involved in chromosome-related functions. , 2000, Genome research.

[158]  B. Halliwell,et al.  No Evidence for Increased Oxidative Damage to Lipids, Proteins, or DNA in Huntington's Disease , 2000, Journal of neurochemistry.

[159]  D. Manners,et al.  Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy , 2000, Annals of neurology.

[160]  D. Housman,et al.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[161]  A. Hackam,et al.  Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3 , 2000, The Journal of Neuroscience.

[162]  R. Albin,et al.  Decreased striatal monoaminergic terminals in Huntington disease , 2000, Neurology.

[163]  A. Morton,et al.  Mice transgenic for the human Huntington’s disease mutation have reduced sensitivity to kainic acid toxicity , 2000, Brain Research Bulletin.

[164]  D. Rubinsztein,et al.  Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[165]  D. Lowenstein,et al.  Loss of BETA2/NeuroD leads to malformation of the dentate gyrus and epilepsy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[166]  K. Leenders,et al.  Bradykinesia in early Huntington’s disease , 2000, Neurology.

[167]  A H Schapira,et al.  Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse , 2000, Annals of neurology.

[168]  J. D. de Yébenes,et al.  Bradykinesia in Huntington's Disease , 2000, Clinical neuropharmacology.

[169]  S. Hersch,et al.  Huntingtin aggregates may not predict neuronal death in Huntington's disease , 1999 .

[170]  S. Snyder,et al.  Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization , 1999, Nature Medicine.

[171]  D. Sulzer,et al.  Intraneuronal dopamine-quinone synthesis: A review , 1999, Neurotoxicity Research.

[172]  O. Hansson,et al.  Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[173]  D. Price,et al.  Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[174]  J. Penney,et al.  Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease , 1999, Nature.

[175]  Claire-Anne Gutekunst,et al.  Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.

[176]  J. Blenis,et al.  Caspase-8 Is Required for Cell Death Induced by Expanded Polyglutamine Repeats , 1999, Neuron.

[177]  J. Penney,et al.  Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. , 1999, Journal of neuropathology and experimental neurology.

[178]  S. Tabrizi,et al.  Biochemical abnormalities and excitotoxicity in Huntington's disease brain , 1999, Annals of neurology.

[179]  M. Beal,et al.  Increased Vulnerability to 3‐Nitropropionic Acid in an Animal Model of Huntington's Disease , 1998, Journal of neurochemistry.

[180]  J. Baldassare,et al.  Molecular aspects of Huntington's disease , 1998, Journal of neuroscience research.

[181]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[182]  D. Shear,et al.  Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease , 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[183]  M. Dragunow,et al.  Trinucleotide (CAG) repeat length is positively correlated with the degree of DNA fragmentation in Huntington's disease striatum , 1998, Neuroscience.

[184]  M. MacDonald,et al.  Huntingtin: a single bait hooks many species , 1998, Current Opinion in Neurobiology.

[185]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[186]  H. Green,et al.  Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. , 1998, Molecular cell.

[187]  J. Arenas,et al.  Complex I Defect in muscle from patients with Huntington's disease , 1998, Annals of neurology.

[188]  F. Condé,et al.  Partial Inhibition of Brain Succinate Dehydrogenase by 3‐Nitropropionic Acid Is Sufficient to Initiate Striatal Degeneration in Rat , 1998, Journal of neurochemistry.

[189]  S. W. Davies,et al.  Intranuclear Neuronal Inclusions in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation between the Density of Inclusions andIT15CAG Triplet Repeat Length , 1998, Neurobiology of Disease.

[190]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[191]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[192]  S. Augood,et al.  Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease , 1997, Annals of neurology.

[193]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[194]  M. MacDonald,et al.  Heterogeneous Topographic and Cellular Distribution of Huntingtin Expression in the Normal Human Neostriatum , 1997, The Journal of Neuroscience.

[195]  S. Palfi,et al.  Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid , 1997, Neuroscience.

[196]  G. Sedvall,et al.  PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.

[197]  B. Rosen,et al.  Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.

[198]  P Boesiger,et al.  Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.

[199]  M. Hayden,et al.  Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract , 1996, Nature Genetics.

[200]  M. Beal,et al.  Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.

[201]  J. Cooper,et al.  Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.

[202]  P. Sanberg,et al.  Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease , 1995, Brain Research.

[203]  Virginia E. Papaioannou,et al.  Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue , 1995, Nature Genetics.

[204]  Peer Bork,et al.  HEAT repeats in the Huntington's disease protein , 1995, Nature Genetics.

[205]  F. Leblhuber,et al.  Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea , 1995, Journal of the Neurological Sciences.

[206]  A. Joyner,et al.  Inactivation of the mouse Huntington's disease gene homolog Hdh. , 1995, Science.

[207]  M. Beal,et al.  Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[208]  M. Perutz,et al.  Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative diseases. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[209]  S. Floresco,et al.  Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.

[210]  D. Steindler,et al.  DNA End Labeling (TUNEL) in Huntington's Disease and Other Neuropathological Conditions , 1995, Experimental Neurology.

[211]  M. Dragunow,et al.  In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes , 1995, Neuroreport.

[212]  C. Portera-Cailliau,et al.  Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[213]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[214]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[215]  S. Folstein,et al.  Early Loss of Neostriatal Striosome Neurons in Huntington's Disease , 1995, Journal of neuropathology and experimental neurology.

[216]  P. Sanberg,et al.  Intrastriatal 3-nitropropionic acid: a behavioral assessment. , 1994, Neuroreport.

[217]  J T Finch,et al.  Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[218]  T. Bolwig,et al.  A Study of Psychiatric Morbidity in Patients with Huntington's Disease, Their Relatives, and Controls , 1993, British Journal of Psychiatry.

[219]  B. Rosen,et al.  Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.

[220]  H. Herzog,et al.  Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease , 1993, Journal of Neurology.

[221]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[222]  B. Hyman,et al.  Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate , 1993, Journal of neurochemistry.

[223]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[224]  Elsdon Storey,et al.  Excitotoxin Lesions in Primates as a Model for Huntington's Disease: Histopathologic and Neurochemical Characterization , 1993, Experimental Neurology.

[225]  B. Rosen,et al.  Age‐Dependent Vulnerability of the Striatum to the Mitochondrial Toxin 3‐Nitropropionic Acid , 1993, Journal of neurochemistry.

[226]  J. Penney,et al.  Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.

[227]  I. Heuser,et al.  The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease , 1991, Biological Psychiatry.

[228]  H. Kremer,et al.  The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease , 1991, Neuroscience Letters.

[229]  M. Beal,et al.  Chronic quinolinic acid lesions in rats closely resemble Huntington's disease , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[230]  Scott T. Grafton,et al.  A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease , 1990, Annals of neurology.

[231]  H. Herzog,et al.  Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.

[232]  Y. Agid,et al.  Mitochondrial function and parental sex effect in Huntington's disease , 1990, The Lancet.

[233]  A. Reiner,et al.  The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projection neurons: conclusions based on recent findings , 1990, Brain Research Reviews.

[234]  J. Parks,et al.  Evidence for a defect in NADH , 1990, Neurology.

[235]  E Maran,et al.  Atrophy of the Hypothalamic Lateral Tuberal Nucleus in Huntington's Disease , 1990, Journal of neuropathology and experimental neurology.

[236]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[237]  Hitoshi Takahashi,et al.  A quantitative investigation of the substantia nigra in Huntington's disease , 1989, Annals of neurology.

[238]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[239]  P. Thompson,et al.  The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. , 1988, Brain : a journal of neurology.

[240]  R. Ferrante,et al.  Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington's disease striatum , 1987, Brain Research.

[241]  Joseph B. Martin,et al.  Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease , 1987, Brain Research.

[242]  J. Mazziotta,et al.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.

[243]  Joseph B. Martin,et al.  Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum , 1986, Neuroscience Letters.

[244]  M. Hayden,et al.  Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.

[245]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[246]  Ira Shoulson,et al.  Huntington's disease in Venezuela , 1986, Neurology.

[247]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[248]  J. B. Martin,et al.  Selective sparing of a class of striatal neurons in Huntington's disease. , 1985, Science.

[249]  E. Bird,et al.  Regional Mitochondrial Respiratory Activity in Huntington's Disease Brain , 1985, Journal of neurochemistry.

[250]  G. Reynolds,et al.  Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and γ-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases , 1985, Journal of the Neurological Sciences.

[251]  L. Farrer Diabetes mellitus in Huntington disease , 1985, Clinical genetics.

[252]  S. Folstein,et al.  Clinical correlates of dementia and disability in Huntington's disease. , 1984, Journal of clinical neuropsychology.

[253]  C. Nahmias,et al.  Reduced striatal glucose consumption and prolonged reaction time are early features in Huntington's disease , 1984, Journal of the Neurological Sciences.

[254]  S. Folstein,et al.  The association of affective disorder with Huntington's Disease in a case series and in families , 1983, Psychological Medicine.

[255]  C. Markham,et al.  Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.

[256]  E. Chiu,et al.  Causes of death in Huntington's Disease , 1982, The Medical journal of Australia.

[257]  H. Fibiger,et al.  BODY WEIGHT AND DIETARY FACTORS IN HUNTINGTON'S DISEASE PATIENTS COMPARED WITH MATCHED CONTROLS , 1981, The Medical journal of Australia.

[258]  P. Swanson,et al.  Biochemical abnormalities in Huntington's chorea brains , 1974, Neurology.

[259]  R. Terry,et al.  STUDIES ON BRAIN BIOPSIES OF PATIENTS WITH HUNTINGTON'S CHOREA , 1974, Journal of neuropathology and experimental neurology.

[260]  D. Sax,et al.  Increased frequency of diabetes mellitus in patients with Huntington's chorea. , 1972, Lancet.

[261]  K. Dewhurst,et al.  Socio-Psychiatric Consequences of Huntington's Disease , 1970, British Journal of Psychiatry.

[262]  Matthew Menear,et al.  Brain imaging and cognitive dysfunctions in Huntington's disease. , 2006, Journal of psychiatry & neuroscience : JPN.

[263]  Steven P Gygi,et al.  Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. , 2005, Nature.

[264]  H. Tanila,et al.  Orexin loss in Huntington's disease. , 2005, Human molecular genetics.

[265]  L. Goldstein,et al.  Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. , 2005, Archives of neurology.

[266]  V. Hachinski,et al.  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Authors' reply , 2004 .

[267]  M. Marsh,et al.  The on-off story of protein palmitoylation. , 2003, Trends in cell biology.

[268]  R. Schwarcz,et al.  3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease? , 2003, Advances in experimental medicine and biology.

[269]  M. Tsai,et al.  Neogenesis of beta-cells in adult BETA2/NeuroD-deficient mice. , 2002, Molecular endocrinology.

[270]  R. Kopito,et al.  Impairment of the ubiquitin-proteasome system by protein aggregation. , 2001, Science.

[271]  S. Hersch,et al.  Huntington aggregates may not predict neuronal death in Huntington's disease. , 1999, Annals of neurology.

[272]  B R Rosen,et al.  Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. , 1993, Neurology.

[273]  Ira Shoulson,et al.  Huntington's disease in venezuela: 7 years of follow‐up on symptomatic and asymptomatic individuals , 1990, Movement disorders : official journal of the Movement Disorder Society.

[274]  S. Folstein,et al.  Huntington disease in Maryland: clinical aspects of racial variation. , 1987, American journal of human genetics.

[275]  S. W. Davies,et al.  No evidence for preservation of somatostatin-containing neurons after intrastriatal injections of quinolinic acid , 1987, Nature.

[276]  Michel Cyr,et al.  The FASEB Journal • FJ Express Full-Length Article Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin , 2022 .

[277]  D. Joel,et al.  Full-length Review , 2022 .